Given the increased risk for PD in both GD patients and carriers [55], with between 7 and 20% of patients with PD carrying a GBA mutation [56], accumulation of glucosylceramide and its metabolites represent potential targets for neurodegenerative treatment. The gene discussed is GBA1; the disease is Parkinson disease.